<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0123-9392</journal-id>
<journal-title><![CDATA[Infectio]]></journal-title>
<abbrev-journal-title><![CDATA[Infect.]]></abbrev-journal-title>
<issn>0123-9392</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Infectología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0123-93922022000400441</article-id>
<article-id pub-id-type="doi">10.22354/24223794.1094</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Advances and Challenges in COVID-19 Vaccination in Latin American: A public health perspective]]></article-title>
<article-title xml:lang="es"><![CDATA[Avances y Retos en la Vacunación contra COVID-19 en América Latina: Una perspectiva desde la salud pública]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernandez-Guzman]]></surname>
<given-names><![CDATA[Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chavez-Cruzado]]></surname>
<given-names><![CDATA[Edward]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Diaz-Velez]]></surname>
<given-names><![CDATA[Cristian]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Galvez-Olortegui]]></surname>
<given-names><![CDATA[Tomas]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rosa]]></surname>
<given-names><![CDATA[Esteban Vergara-de la]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Morales]]></surname>
<given-names><![CDATA[Alfonso J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Galvez-Olortegui]]></surname>
<given-names><![CDATA[Jose]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Scientia Clinical and Epidemiological Research Institute  ]]></institution>
<addr-line><![CDATA[Trujillo ]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad San Ignacio de Loyola  ]]></institution>
<addr-line><![CDATA[Lima ]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Privada Antenor Orrego Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Trujillo ]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad Privada Antenor Orrego Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Trujillo ]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Scientia Clinical and Epidemiological Research Institute  ]]></institution>
<addr-line><![CDATA[Trujillo ]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Hospital Nacional Guillermo Almenara Irigoyen  ]]></institution>
<addr-line><![CDATA[Lima ]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Universidad Nacional de Trujillo  ]]></institution>
<addr-line><![CDATA[Trujillo ]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Universidad Cientifica del Sur  ]]></institution>
<addr-line><![CDATA[Lima ]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Hospital Universitario Central de Asturias  ]]></institution>
<addr-line><![CDATA[Oviedo ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>26</volume>
<numero>4</numero>
<fpage>441</fpage>
<lpage>449</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0123-93922022000400441&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0123-93922022000400441&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0123-93922022000400441&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The vaccination against SARS-CoV-2 has been recognized as a priority strategy to safeguard public health. However, disparities in productive, acquisitive and distributional capacity have led to delays in immunization, particularly in low- and middle-income countries. Consequently, global coverage is expected to achieve herd immunity against COVID-19 by 2023 or 2024, although with highly variable coverage percentages among countries. In Latin America, immunization against COVID-19 faces different challenges to achieve herd immunity. To date (February 6, 2022), the countries that had several doses needed to immunize their populations with at least two doses (number of doses between population) were Peru (520.7%), Chile (458.4%), Argentina (298.0%), Brazil (236.6%), Bolivia (206.0%) and Uruguay (unconfirmed doses). On the other hand, Uruguay (210.7%) and Chile (238.3%) have applied twice as many doses as their populations. Argentina (194.3%), Brazil (173.6%), Ecuador (170.3%), Peru (170.3%), Costa Rica (161.1%), and Panama (153.5%) are on the way to achieving this goal. In addition, Latin American countries also showed an insufficient distribution of vaccines and a storage capacity limited to only a few cities and multiple frequencies of vaccine hesitancy. Due to these scenarios, the production of more vaccine doses and equitable distribution to the rest of the population within the Latin American region should remain a public health priority to achieve collective immunity in the shortest time possible.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La vacunación contra el SARS-CoV-2 ha sido reconocida como una estrategia prioritaria para salvaguardar la salud pública. Sin embargo, las disparidades en la capacidad productiva, adquisitiva y de distribución han provocado retrasos en la inmunización, en particular en los países de ingresos bajos y medianos. En consecuencia, se espera que la cobertura mundial alcance la inmunidad colectiva contra la COVID-19 para 2023 o 2024, aunque con porcentajes de cobertura muy variables entre los países. En América Latina, la inmunización contra el COVID-19 enfrenta diferentes desafíos para lograr la inmunidad colectiva. A la fecha (6 de febrero de 2022), los países que tenían varias dosis necesarias para inmunizar a sus poblaciones con al menos dos dosis (número de dosis entre población) eran Perú (520,7%), Chile (458,4%), Argentina (298,0%), Brasil (236,6%), Bolivia (206,0%) y Uruguay (dosis no confirmadas). Por otro lado, Uruguay (210,7%) y Chile (238,3%) han aplicado el doble de dosis que sus poblaciones. Argentina (194,3%), Brasil (173,6%), Ecuador (170,3%), Perú (170,3%), Costa Rica (161,1%) y Panamá (153,5%) están en camino de lograr este objetivo. Además, los países latinoamericanos también mostraron una distribución insuficiente de vacunas y una capacidad de almacenamiento limitada a solo unas pocas ciudades y múltiples frecuencias de reticencia a la vacuna. Debido a estos escenarios, la producción de más dosis de vacuna y la distribución equitativa al resto de la población dentro de la región latinoamericana debe seguir siendo una prioridad de salud pública para lograr la inmunidad colectiva en el menor tiempo posible.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Vaccines]]></kwd>
<kwd lng="en"><![CDATA[Coronavirus infections]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[Latin America]]></kwd>
<kwd lng="en"><![CDATA[Public Health (Source: MESH)]]></kwd>
<kwd lng="es"><![CDATA[Vacunas]]></kwd>
<kwd lng="es"><![CDATA[Coronavirus]]></kwd>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[América Latina]]></kwd>
<kwd lng="es"><![CDATA[Salud Pública]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sohrabi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alsafi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[O&amp;apos;Neill]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[World Health Organization declares global emergency A review of the 2019 novel coronavirus (COVID-19)]]></article-title>
<source><![CDATA[Int J Surg]]></source>
<year>2020</year>
<volume>76</volume>
<numero>2020</numero>
<issue>2020</issue>
<page-range>71-6</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Johns Hopkins Universiity</collab>
<source><![CDATA[Mapa COVID-19 - Centro de recursos de coronavirus Johns Hopkins. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kupferschmidt]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Race to find COVID-19 treatments accelerates]]></article-title>
<source><![CDATA[Science (80- )]]></source>
<year>2020</year>
<volume>367</volume>
<numero>6485</numero>
<issue>6485</issue>
<page-range>1412-3</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[COVID-19 vaccines]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Izda]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Jeffries]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Sawalha]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 A review of therapeutic strategies and vaccine candidates]]></article-title>
<source><![CDATA[Clin Immunol]]></source>
<year>2021</year>
<volume>222</volume>
<page-range>108634</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[Draft landscape and tracker of COVID-19 candidate vaccines]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plotkin]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccines past, present and future]]></article-title>
<source><![CDATA[Nat Med]]></source>
<year>2005</year>
<volume>11</volume>
<numero>S4</numero>
<issue>S4</issue>
<page-range>S5-S11</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soleimanpour]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yaghoubi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 vaccine where are we now and where should we go?]]></article-title>
<source><![CDATA[Expert Rev Vaccines]]></source>
<year>2021</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-44</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karpiñski]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[OZarowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Seremak-Mrozikiewicz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wolski]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wlodkowic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2020 race towards SARS-CoV-2 specific vaccines]]></article-title>
<source><![CDATA[Theranostics]]></source>
<year>2021</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1690-702</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calina]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Docea]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[Petrakis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Towards effective COVID-19 vaccines Updates, perspectives and challenges (Review)]]></article-title>
<source><![CDATA[Int J Mol Med]]></source>
<year>2020</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-16</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Munira]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Hendriks]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Atmosukarto]]></surname>
<given-names><![CDATA[II]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A cost analysis of producing vaccines in developing countries]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2019</year>
<volume>37</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1245-51</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeyanathan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Afkhami]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Smaill]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Lichty]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Xing]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunological considerations for COVID-19 vaccine strategies]]></article-title>
<source><![CDATA[Nat Rev Immunol]]></source>
<year>2020</year>
<volume>20</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>615-32</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rouphael]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An mRNA Vaccine against SARS-CoV-2 - Preliminary Report]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>383</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1920-31</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Polack]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kitchin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>383</volume>
<numero>27</numero>
<issue>27</issue>
<page-range>2603-15</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baraniuk]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What do we know about China&amp;apos;s covid-19 vaccines BMJ]]></article-title>
<source><![CDATA[April]]></source>
<year>2021</year>
<page-range>n912</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>Duke Global Health Innovation Center</collab>
<source><![CDATA[Tracking COVID-19 Vaccine Purchases Across The Globe | Launch and Scale Speedometer]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes IV]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[DeWald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenbaum]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pisani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Orenstein]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ensuring Equitable Access To COVID-19 Vaccines In The US Current System Challenges And Opportunities]]></article-title>
<source><![CDATA[Health Aff]]></source>
<year>2021</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>62-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slaoui]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hepburn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Developing Safe and Effective Covid Vaccines - Operation Warp Speed&amp;apos;s Strategy and Approach]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>383</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1701-3</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ortiz-Prado]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Espín]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vásconez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Burneo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kyriakidis]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[López-Cortés]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccine market and production capabilities in the Americas]]></article-title>
<source><![CDATA[Trop Dis Travel Med Vaccines]]></source>
<year>2021</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kupferschmidt]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccine nationalism' threatens global plan to distribute COVID-19 shots fairly]]></article-title>
<source><![CDATA[Science]]></source>
<year>2020</year>
<numero>80</numero>
<issue>80</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Usher]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A beautiful idea how COVAX has fallen short]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<numero>10292</numero>
<issue>10292</issue>
<page-range>2322-5</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[BBC News Mundo - Los países en América Latina en los que desarrollan proyectos de vacunas contra la covid-19]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vacunas contra el SARS-CoV-2 ¿son una realidad para América Latina?]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2020</year>
<volume>40</volume>
<page-range>424-6</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andrus]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Evans-Gilbert]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perspectives on Battling COVID-19 in Countries of Latin America and the Caribbean]]></article-title>
<source><![CDATA[Am J Trop Med Hyg]]></source>
<year>2020</year>
<volume>103</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>593-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<collab>El País</collab>
<source><![CDATA[México y Argentina comienzan el reparto de las vacunas de AstraZeneca con un retraso de tres meses]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="">
<collab>Food and Drug Administration, Center for Biologics Evaluation and Research</collab>
<source><![CDATA[Contains Nonbinding Recommendations | Emergency Use Authorization for Vaccines to Prevent COVID-19 | Guidance for Industry Preface]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urrunaga-Pastor]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bendezu-Quispe]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera-Añazco]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean]]></article-title>
<source><![CDATA[Travel Med Infect Dis]]></source>
<year>2021</year>
<volume>41</volume>
<page-range>102059</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Pasquale]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bonanni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Garçon]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Stanberry]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[El-Hodhod]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccine safety evaluation Practical aspects in assessing benefits and risks]]></article-title>
<collab>Tavares Da Silva F</collab>
<source><![CDATA[Vaccine]]></source>
<year>2016</year>
<volume>34</volume>
<numero>52</numero>
<issue>52</issue>
<page-range>6672-80</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lipsitch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dean]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Understanding COVID-19 vaccine efficacy]]></article-title>
<source><![CDATA[Science (80- )]]></source>
<year>2020</year>
<volume>370</volume>
<numero>6518</numero>
<issue>6518</issue>
<page-range>763-5</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bingham]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plan now to speed vaccine supply for future pandemics]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2020</year>
<volume>586</volume>
<numero>7828</numero>
<issue>7828</issue>
<page-range>171</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hessel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pandemic influenza vaccines meeting the supply, distribution and deployment challenges]]></article-title>
<source><![CDATA[Influenza Other Respi Viruses]]></source>
<year>2009</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>165-70</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meo]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Bukhari]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Akram]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Meo]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Klonoff]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 vaccines comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines]]></article-title>
<source><![CDATA[Eur Rev Med Pharmacol Sci]]></source>
<year>2021</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1663-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="">
<collab>The Joint Committee on Vaccination and Immunization (JCVI)</collab>
<source><![CDATA[JCVI issues advice on the AstraZeneca COVID-19 vaccine]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saciuk]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kertes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shamir Stein]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ekka Zohar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of a third dose of BNT162b2 mRNA vaccine]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="">
<collab>Centers for Disease Control and Prevention</collab>
<source><![CDATA[About Variants of the Virus that Causes COVID-19 | CDC]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kistler]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Bedford]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229E bioRxiv]]></article-title>
<source><![CDATA[January]]></source>
<year>2021</year>
<page-range>2020</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shum]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020]]></article-title>
<source><![CDATA[Euro surveill]]></source>
<year>2021</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Callaway]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Delta coronavirus variant scientists brace for impact]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2021</year>
<volume>595</volume>
<numero>7865</numero>
<issue>7865</issue>
<page-range>17-8</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopez Bernal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Andrews]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gower]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Simmons]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Thelwall]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of Covid-19 Vaccines against the B 1.617.2 (Delta) Variant]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>385</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>585-94</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferré]]></surname>
<given-names><![CDATA[Valentine Marie]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA["Omicron SARS-CoV-2 Variant: What We Know and What We Don't."]]></article-title>
<source><![CDATA[Anaesthesia Critical Care &amp; PainMedicine]]></source>
<year>2022</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>100998</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Debes]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Egbert]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
</person-group>
<source><![CDATA[Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and other variants in paired samples after two or three doses of mRNA vaccine. Preprint. medRxiv]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minka]]></surname>
<given-names><![CDATA[S.O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA["A Tabulated Summary of the Evidence on Humoral and Cellular Responses to the SARS-CoV-2 Omicron VOC, as Well as Vaccine Efficacy against This Variant."]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Minka]]></surname>
<given-names><![CDATA[F.H]]></given-names>
</name>
</person-group>
<source><![CDATA[Immunology Letters]]></source>
<year>2022</year>
<numero>243</numero>
<issue>243</issue>
<page-range>38-43</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eguia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[KHD]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens-Ayers]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A human coronavirus evolves antigenically to escape antibody immunity bioRxiv]]></article-title>
<source><![CDATA[January]]></source>
<year>2020</year>
<page-range>2020</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fontes-Garfias]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera bioRxiv Prepr Serv Biol]]></article-title>
<source><![CDATA[January]]></source>
<year>2021</year>
<page-range>2021</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luchsinger]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Hillyer]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccine efficacy probable against COVID-19 variants Sills J, ed]]></article-title>
<source><![CDATA[Science (80- )]]></source>
<year>2021</year>
<volume>371</volume>
<numero>6534</numero>
<issue>6534</issue>
<page-range>1116</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="">
<collab>Our World in Data</collab>
<source><![CDATA[COVID-19 vaccine doses administered]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="">
<collab>Office for National Statistics - United Kingdom</collab>
<source><![CDATA[Deaths involving COVID-19 by vaccination status, England: deaths occurring between January 1 and October 31 2021]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDonnell]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Van Exan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lloyd]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 Vaccine Predictions]]></article-title>
<source><![CDATA[Cent Glob Dev]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomes]]></surname>
<given-names><![CDATA[MGM]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[MU]]></given-names>
</name>
<name>
<surname><![CDATA[Corder]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold [published online ahead of print, 2022 February 18] J Theor]]></article-title>
<source><![CDATA[Biol]]></source>
<year>2022</year>
<volume>540</volume>
<page-range>111063</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<collab>Prüß BM</collab>
<article-title xml:lang=""><![CDATA[Current State of the First COVID-19 Vaccines]]></article-title>
<source><![CDATA[Vaccines]]></source>
<year>2021</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>30</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social de Colombia</collab>
<source><![CDATA[Reducción de mortalidad en mayores de 80 sugiere efectividad de la vacuna]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Stuart]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Greenland]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Van-Tam]]></surname>
<given-names><![CDATA[JSN]]></given-names>
</name>
<name>
<surname><![CDATA[Snape]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heterologous vaccination strategy for containing COVID-19 pandemic medRxiv]]></article-title>
<source><![CDATA[January]]></source>
<year>2021</year>
<page-range>2021</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Callaway]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mix-and-match COVID vaccines trigger potent immune response]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2021</year>
<volume>593</volume>
<numero>7860</numero>
<issue>7860</issue>
<page-range>491</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Médica]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Las CC.AA podrán administrar la segunda dosis de AstraZeneca a los menores de 60]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urrunaga-Pastor]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bendezu-Quispe]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera-Añazco]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean]]></article-title>
<source><![CDATA[Travel Med Infect Dis]]></source>
<year>2021</year>
<volume>41</volume>
<page-range>102059</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Macinko]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Seixas B]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Which older Brazilians will accept a COVID-19 vaccine Cross-sectional evidence from the Brazilian Longitudinal Study of Aging (ELSI-Brazil)]]></article-title>
<collab>Mambrini JV de M.Lima-Costa MF</collab>
<source><![CDATA[BMJ Open]]></source>
<year>2021</year>
<volume>11</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lazarus J]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ratzan]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Palayew]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A global survey of potential acceptance of a COVID-19 vaccine]]></article-title>
<source><![CDATA[Nat Med]]></source>
<year>2021</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>225-8</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrera-Añazco]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Uyen-Cateriano]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Urrunaga-Pastor]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia y factores asociados a la intención de vacunarse contra la COVID-19 en el Perú]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Publica]]></source>
<year>2021</year>
<volume>38</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>381-90</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarasty]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Carpio]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Hudson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrero-Ochoa]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Borja]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The demand for a COVID-19 vaccine in Ecuador]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2020</year>
<volume>38</volume>
<numero>51</numero>
<issue>51</issue>
<page-range>8090-8</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Argote Tironi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Barham]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Zuckerman Daly]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gerez]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Marshall]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pocasangre]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Messages that increase COVID-19 vaccine acceptance Evidence from online experiments in six Latin American countries. Delcea C, ed]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2021</year>
<volume>16</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
